<div id="readability-page-1"><p>LabGenius Therapeutics announced a second collaboration with Sanofi. This collaboration combines LabGenius' AI/ML-driven antibody design capabilities with Sanofi's expertise in the development of therapeutic NANOBODY molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA platform to optimise NANOBODY molecules for multiple new targets in the area of inflammation.</p></div>

赛诺菲

<p>LabGenius Therapeutics 宣布与赛诺菲进行第二次合作。此次合作将 LabGenius 的 AI/ML 驱动抗体设计能力与赛诺菲 在治疗 NANOBODY 分子开发方面的专业知识相结合，以共同优化具有治疗价值的蛋白质特性。在第一次合作取得成功之后，LabGenius 将应用 EVA 平台来优化针对炎症领域多个新靶点的 NANOBODY 分子</p>

LabGenius Therapeutics 宣布与赛诺菲合作多个由 AI/ML 驱动的抗体优化项目